Cara

Is marriage modern? Anna Kate Blair's novel poses the question, but doesn't answer it

Retrieved on: 
Tuesday, October 3, 2023

This is the circuitous premise of Australian writer Anna Kate Blair’s debut novel, The Modern, set in contemporary New York and centred on the life, half-loves and near-loves of Sophia, an Australian research fellow at MoMA (the Museum of Modern Art).

Key Points: 
  • This is the circuitous premise of Australian writer Anna Kate Blair’s debut novel, The Modern, set in contemporary New York and centred on the life, half-loves and near-loves of Sophia, an Australian research fellow at MoMA (the Museum of Modern Art).
  • Review: The Modern – Anna Kate Blair (Scribner) Sophia’s engagement shakes out a constellation of loose questions about potential choices, possibilities and limitations.
  • When Robert departs, Sophia meets the mercurial, filament-like Cara, an unlikely assistant in a little-frequented New York wedding boutique.

Is marriage modern?

    • The question “Is marriage modern?” is less the fulcrum of Sophia’s personal narrative than, increasingly, a perplexing nonsense rhyme, or rhetorical question weighed down by its own glowering question mark.
    • Is marriage modern?
    • In the context of same-sex marriage, which Blair touches upon, marriage is modern, so long as you don’t drill down to its ideological underpinnings: the history of marriage as property transfer, its requisite reproductive labour, the spectacle of grim-lipped, decades-long resentments sustained under the oath of “til death do us part”.
    • By what barometer might we gauge “modernity” in marriage?

Smacked in the face by a dress

    • A flounce-ridden, gorgeously deep-red wedding dress in a Moonee Ponds wedding boutique window.
    • For one second, I entertained the idea of a wedding, but only because of that dress.
    • But the phenomenon itself – the overweening presence of the wedding dress in young women’s lives – remains under-explored.

Modern art ‘at every turn’

    • If the novel’s central question is not answered or adequately dissected, questions of modernity in art are more fulsomely, if curatorially, examined.
    • The Modern tosses “modern” artists and art at the reader at every turn, assuming a familiarity with art history on the reader’s part.
    • The Modern overflows with ideas: musings on modern art, and on the masculinist orientation of art institutions, in which female curatorial assistants doggedly do the work their male supervisors put their names to.

Curated, rather than known

    • She is curated rather than known; she’s a collection of iterations.
    • Perhaps this is Blair’s intention: Hartigan as surface, knowable only through her work, her private self inured to the public gaze.
    • But every character in The Modern feels somewhat like a bit-part: fleeting, insubstantial, or, in Robert’s case, downright wooden.

Scale Logic Becomes Exclusive North American VAD for ObviousFuture

Retrieved on: 
Thursday, September 14, 2023

Scale Logic, a prominent leader in Media Workflow Solutions, is proud to announce its strategic partnership with ObviousFuture.

Key Points: 
  • Scale Logic, a prominent leader in Media Workflow Solutions, is proud to announce its strategic partnership with ObviousFuture.
  • As the exclusive North American Value-Added Distributor of Cara.One, Scale Logic is set to transform how media professionals handle content search, post-production processes, and overall workflow efficiency.
  • "At Scale Logic, we are committed to identifying leading-edge solutions that enhance our client's productivity and empower their creative endeavors," said Bob Herzan, CEO of Scale Logic.
  • "We are excited to join forces with Scale Logic as the North American Value-Added Distributor of Cara.One," stated Eddi Weinwurm, President at ObviousFuture.

Morgan Prestwich surpasses plans for global growth with five new senior appointments and a leadership promotion within their Executive Search teams across North America and Europe

Retrieved on: 
Monday, June 12, 2023

In a strategic move to enhance the Executive Search Team, Morgan Prestwich has made a number of strategic hires to further enhance its leadership portfolio.

Key Points: 
  • In a strategic move to enhance the Executive Search Team, Morgan Prestwich has made a number of strategic hires to further enhance its leadership portfolio.
  • Spearheading the growth, Morgan Prestwich is delighted to welcome Christian Simon as Chief Operating Officer.
  • Throughout her tenure, Cara has successfully built a number of impressive senior leadership teams for biotech clients in both North America and Europe.
  • Founded in 2010, Morgan Prestwich is a global leading independent life sciences executive search and advisory firm.

Morgan Prestwich surpasses plans for global growth with five new senior appointments and a leadership promotion within their Executive Search teams across North America and Europe

Retrieved on: 
Monday, June 12, 2023

In a strategic move to enhance the Executive Search Team, Morgan Prestwich has made a number of strategic hires to further enhance its leadership portfolio.

Key Points: 
  • In a strategic move to enhance the Executive Search Team, Morgan Prestwich has made a number of strategic hires to further enhance its leadership portfolio.
  • Spearheading the growth, Morgan Prestwich is delighted to welcome Christian Simon as Chief Operating Officer.
  • Throughout her tenure, Cara has successfully built a number of impressive senior leadership teams for biotech clients in both North America and Europe.
  • Founded in 2010, Morgan Prestwich is a global leading independent life sciences executive search and advisory firm.

Cara Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023

STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • – Conference call today at 4:30 p.m. EDT –
    STAMFORD, Conn., May 15, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the first quarter ended March 31, 2023.
  • “The U.S. and global launches of KORSUVA® (difelikefalin) injection / Kapruvia® gained momentum in the first quarter of 2023.
  • Wholesalers shipped 45,720 vials to dialysis centers, the majority of which were Fresenius clinics, during the first quarter of 2023.
  • Vial orders more than doubled quarter to quarter, signifying an acceleration in patient demand.

SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full Year 2022

Retrieved on: 
Monday, April 3, 2023

DALLAS, April 3, 2023 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided a business update and announced its financial and operating results for the fourth quarter ended December 31, 2022.

Key Points: 
  • ET
    Fourth quarter 2022 GAAP net income was $2.8 million, compared with net income of $6.3 million for the fourth quarter 2021.
  • For the fourth quarter 2022, SWK reported total revenue of $9.8 million, a 34.5% decrease compared to $15.0 million for the fourth quarter 2021.
  • For the fourth quarter 2022, GAAP net income was $2.8 million, compared to $6.3 million for the fourth quarter 2021.
  • For the fourth quarter 2022, non-GAAP adjusted net income was $1.6 million, compared with $9.5 million for the fourth quarter 2021.

Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report

Retrieved on: 
Tuesday, March 14, 2023

STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.

Key Points: 
  • STAMFORD, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today released its inaugural Environmental, Social, and Governance (ESG) report highlighting the Company’s efforts in key areas such as corporate governance, diversity and inclusion in the workplace, environmental stewardship and social responsibility.
  • “Our first ESG report establishes a solid reporting baseline of the work underway at Cara Therapeutics that extends beyond our commitment to transforming the way chronic pruritus is treated and reflects our focus on innovating sustainability, operating responsibly and empowering people,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • Highlights of the report include:
    Corporate governance: The Company has implemented a cross-functional ESG Group that will meet on a regular basis and report to the Board of Directors periodically on policy implementation and improvement.
  • Workplace diversity: The Company continues to strengthen its diversity and inclusivity efforts including a gender-balanced leadership team and Board of Directors.

Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, March 6, 2023

STAMFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • During the fourth quarter of 2022, we saw both new clinic and repeat orders driving product uptake, bolstering our confidence in KORSUVA’s long-term potential,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
  • In the fourth quarter of 2022, wholesalers shipped 20,844 vials to dialysis centers following initial inventory building in the third quarter of 2022, predominantly at Fresenius clinics.
  • The Company expects launches in countries in Europe to continue in 2023, following launches of Kapruvia in Austria, Germany, and Sweden during the fourth quarter of 2022.
  • With the approval of Kapruvia in Australia in the fourth quarter of 2022, all four Access Consortium countries have approved the product.

Research Funding Available for Preeclampsia and Related Pregnancy Disorders

Retrieved on: 
Wednesday, February 8, 2023

SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- Preeclampsia Foundation Canada announced today at the Society for Maternal-Fetal Medicine's (SMFM) 43rd Annual Meeting – The Pregnancy Meeting™ – that applications are now being accepted for its 2023 Vision Grant program.

Key Points: 
  • Preeclampsia Foundation Canada will award two medical research Vision Grants to study preeclampsia and related hypertensive disorders of pregnancy.
  • Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
  • Since 2016, the Preeclampsia Foundation Canada's Vision Grant annual program has invested more than $180,000 in novel research with the goal of supporting new, potentially groundbreaking concepts.
  • "Preeclampsia Foundation Canada looks forward to supporting ambitious and innovative research that will lead to improved maternal and infant health," said Violet Mateljan, President of the Preeclampsia Foundation Canada Board of Directors.

Boston Insurance Brokerage LLC ("BIB") has announced the promotion of Cara MacDonald to VP of Workers' Compensation

Retrieved on: 
Tuesday, January 10, 2023

"Cara has definitely earned the title of VP here at BIB," said Keith Driscoll, Boston Insurance Brokerage's CEO.

Key Points: 
  • "Cara has definitely earned the title of VP here at BIB," said Keith Driscoll, Boston Insurance Brokerage's CEO.
  • "When I was getting my Masters in Education, the plan was to teach youth in a school setting," said Cara.
  • As VP, Cara is tasked with growing and maintaining the division's book of business, as well as developing carrier and agent relationships.
  • Boston Insurance Brokerage is a wholesale brokerage that offers commercial insurance products.